TPST
Tempest Therapeutics, Inc.
Price Chart
Latest Quote
$0.51
-0.00 (-0.55%)
Current Price
| Previous Close | $0.51 |
| Open | $0.52 |
| Day High | $0.53 |
| Day Low | $0.51 |
| Volume | 71,636 |
Stock Information
| Shares Outstanding | 16.89M |
| Total Debt | $7.56M |
| Cash Equivalents | $779K |
| Net Income | $-40.47M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $8.63M |
| EPS (TTM) | $-3.93 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $14.94M |
| Income | $-40.47M |
| Book/sh | $-0.07 |
| Cash/sh | $0.05 |
| Employees | 4 |
Financial Ratios
| Quick Ratio | 0.17 |
| Current Ratio | 0.38 |
Returns & Margins
| ROA | -79.37% |
| ROE | -931.14% |
Ownership
| Insider Ownership | 30.07% |
| Institutional Ownership | 27.98% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.42 |
| P/B | -7.51 |
Analyst Data
| Recommendation | none |
| Target Price | $7.00 |
Technical Indicators
| SMA20 | $nan |
| SMA50 | $nan |
| SMA200 | $nan |
| ATR | nan |
| Shares Float | 11.08M |
| Short Float | 7.25% |
| Short Ratio | 0.09 |
| Volatility | -1.71 |
| Rel Volume | 0.26 |
Performance History
| Week | nan% |
| Month | nan% |
| Quarter | nan% |
| 6 Months | nan% |
| YTD | nan% |
| Year | nan% |
| 3 Years | nan% |
| 5 Years | nan% |
| 10 Years | nan% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $nan | 71,636 |
| 2026-10-26 | $0.51 | 66,100 |
| 2026-10-23 | $0.51 | 52,200 |
| 2026-10-22 | $0.52 | 188,500 |
| 2026-10-21 | $0.53 | 368,300 |
| 2026-10-20 | $0.58 | 138,300 |
| 2026-10-19 | $0.60 | 127,400 |
| 2026-10-16 | $0.62 | 67,100 |
| 2026-10-15 | $0.63 | 120,800 |
| 2026-10-14 | $0.63 | 179,100 |
| 2026-10-13 | $0.68 | 228,700 |
| 2026-10-12 | $0.74 | 163,600 |
| 2026-10-09 | $0.76 | 180,100 |
| 2026-10-08 | $0.77 | 147,100 |
| 2026-10-07 | $0.79 | 307,400 |
| 2026-10-06 | $0.79 | 217,600 |
| 2026-10-05 | $0.79 | 155,200 |
| 2026-10-02 | $0.81 | 2,271,700 |
| 2026-10-01 | $0.81 | 153,400 |
| 2026-09-30 | $0.83 | 265,000 |
| 2026-09-29 | $0.81 | 152,300 |
| 2026-09-28 | $0.83 | 256,400 |
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on TPST.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $207,000 | $1,316,000 | $1,449,000 | $1,618,000 |
| Total Expenses | $26,575,000 | $42,026,000 | $29,157,000 | $34,640,000 |
| Net Non Operating Interest Income Expense | $313,000 | $183,000 | $-334,000 | $-1,018,000 |
| Interest Expense Non Operating | $207,000 | $1,316,000 | $1,449,000 | $1,618,000 |
| Operating Expense | $26,575,000 | $42,026,000 | $29,157,000 | $34,640,000 |
| General And Administrative Expense | $13,969,000 | $13,550,000 | $11,659,000 | $12,113,000 |
| Other Income Expense | - | - | $15,000 | $-51,000 |
| Other Non Operating Income Expenses | - | - | $15,000 | $-51,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Net Interest Income | $313,000 | $183,000 | $-334,000 | $-1,018,000 |
| Interest Income | $520,000 | $1,499,000 | $1,115,000 | $600,000 |
| Normalized Income | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Net Income From Continuing And Discontinued Operation | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Total Operating Income As Reported | $-26,575,000 | $-42,026,000 | $-29,157,000 | $-34,640,000 |
| Net Income Common Stockholders | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Net Income | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Net Income Including Noncontrolling Interests | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Net Income Continuous Operations | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Pretax Income | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Interest Income Non Operating | $520,000 | $1,499,000 | $1,115,000 | $600,000 |
| Operating Income | $-26,575,000 | $-42,026,000 | $-29,157,000 | $-34,640,000 |
| Per Share | ||||
| Diluted EPS | $-6.33 | $-19.50 | $-24.83 | $-40.17 |
| Basic EPS | $-6.33 | $-19.50 | $-24.83 | $-40.17 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-25,789,000 | $-40,138,000 | $-27,661,000 | $-33,453,000 |
| Reconciled Depreciation | $266,000 | $389,000 | $381,000 | $638,000 |
| EBITDA (Bullshit earnings) | $-25,789,000 | $-40,138,000 | $-27,661,000 | $-33,453,000 |
| EBIT | $-26,055,000 | $-40,527,000 | $-28,042,000 | $-34,091,000 |
| Diluted Average Shares | $4,148,815 | $3,382,432 | $1,185,861 | $888,947 |
| Basic Average Shares | $4,148,815 | $3,382,432 | $1,185,861 | $888,947 |
| Diluted NI Availto Com Stockholders | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Research And Development | $12,606,000 | $28,476,000 | $17,498,000 | $22,527,000 |
| Selling General And Administration | $13,969,000 | $13,550,000 | $11,659,000 | $12,113,000 |
| Other Gand A | $13,969,000 | $13,550,000 | $11,659,000 | $12,113,000 |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $6,668,000 | $19,126,000 | $26,768,000 | $18,111,000 |
| Total Assets | $16,931,000 | $41,488,000 | $51,603,000 | $46,089,000 |
| Total Non Current Assets | $8,662,000 | $10,014,000 | $11,240,000 | $13,139,000 |
| Other Non Current Assets | $517,000 | $485,000 | $448,000 | $429,000 |
| Current Assets | $8,269,000 | $31,474,000 | $40,363,000 | $32,950,000 |
| Other Current Assets | $355,000 | $535,000 | $96,000 | $263,000 |
| Prepaid Assets | $207,000 | $671,000 | $1,037,000 | $1,007,000 |
| Cash Cash Equivalents And Short Term Investments | $7,707,000 | $30,268,000 | $39,230,000 | $31,230,000 |
| Cash And Cash Equivalents | $7,707,000 | $30,268,000 | $39,230,000 | $31,230,000 |
| Receivables | - | - | $0 | $450,000 |
| Other Receivables | - | - | - | $450,000 |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $8,141,000 | $15,365,000 | $20,661,000 | $22,114,000 |
| Long Term Debt And Capital Lease Obligation | $6,949,000 | $8,142,000 | $15,424,000 | $20,701,000 |
| Current Debt And Capital Lease Obligation | $1,192,000 | $7,223,000 | $5,237,000 | $1,413,000 |
| Current Debt | - | $6,354,000 | $4,285,000 | - |
| Other Current Borrowings | - | $6,354,000 | $4,285,000 | - |
| Long Term Debt | - | - | $6,264,000 | $10,371,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,263,000 | $22,362,000 | $24,835,000 | $27,978,000 |
| Total Non Current Liabilities Net Minority Interest | $6,949,000 | $8,142,000 | $15,424,000 | $20,701,000 |
| Current Liabilities | $3,314,000 | $14,220,000 | $9,411,000 | $7,277,000 |
| Payables And Accrued Expenses | $1,975,000 | $5,235,000 | $2,631,000 | $4,616,000 |
| Interest Payable | $0 | $59,000 | $113,000 | $97,000 |
| Payables | $1,038,000 | $2,450,000 | $845,000 | $1,108,000 |
| Accounts Payable | $1,038,000 | $2,450,000 | $845,000 | $1,108,000 |
| Equity | ||||
| Common Stock Equity | $6,668,000 | $19,126,000 | $26,768,000 | $18,111,000 |
| Total Equity Gross Minority Interest | $6,668,000 | $19,126,000 | $26,768,000 | $18,111,000 |
| Stockholders Equity | $6,668,000 | $19,126,000 | $26,768,000 | $18,111,000 |
| Retained Earnings | $-233,368,000 | $-207,106,000 | $-165,263,000 | $-135,772,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $4,927,161 | $3,382,432 | $1,695,788 | $809,118 |
| Share Issued | $4,927,161 | $3,382,432 | $1,695,788 | $809,118 |
| Tangible Book Value | $6,668,000 | $19,126,000 | $26,768,000 | $18,111,000 |
| Invested Capital | $6,668,000 | $25,480,000 | $37,317,000 | $28,482,000 |
| Working Capital | $4,955,000 | $17,254,000 | $30,952,000 | $25,673,000 |
| Capital Lease Obligations | $8,141,000 | $9,011,000 | $10,112,000 | $11,743,000 |
| Total Capitalization | $6,668,000 | $19,126,000 | $33,032,000 | $28,482,000 |
| Additional Paid In Capital | $240,031,000 | $226,229,000 | $192,009,000 | $153,872,000 |
| Capital Stock | $5,000 | $3,000 | $22,000 | $11,000 |
| Common Stock | $5,000 | $3,000 | $22,000 | $11,000 |
| Long Term Capital Lease Obligation | $6,949,000 | $8,142,000 | $9,160,000 | $10,330,000 |
| Current Capital Lease Obligation | $1,192,000 | $869,000 | $952,000 | $1,413,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $147,000 | $1,762,000 | $1,543,000 | $1,248,000 |
| Current Accrued Expenses | $937,000 | $2,785,000 | $1,786,000 | $3,508,000 |
| Net PPE | $8,145,000 | $9,529,000 | $10,792,000 | $12,710,000 |
| Accumulated Depreciation | $-1,453,000 | $-1,320,000 | $-1,025,000 | $-1,361,000 |
| Gross PPE | $9,598,000 | $10,849,000 | $11,817,000 | $14,071,000 |
| Leases | $198,000 | $201,000 | $235,000 | $882,000 |
| Other Properties | $8,986,000 | $10,128,000 | $11,085,000 | $1,061,000 |
| Machinery Furniture Equipment | $414,000 | $520,000 | $497,000 | $478,000 |
| Properties | $0 | $0 | $0 | $0 |
| Buildings And Improvements | - | - | $9,952,000 | $11,650,000 |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-26,820,000 | $-33,462,000 | $-27,527,000 | $-31,634,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-26,820,000 | $-33,027,000 | $-27,357,000 | $-31,072,000 |
| Cash Flow From Continuing Operating Activities | $-26,820,000 | $-33,027,000 | $-27,357,000 | $-31,072,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-435,000 | $-170,000 | $-562,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-435,000 | $-170,000 | $-562,000 |
| Capital Expenditure | - | $-435,000 | $-170,000 | $-562,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,329,000 | $28,591,000 | $35,602,000 | $8,861,000 |
| Financing Cash Flow | $4,259,000 | $24,500,000 | $35,602,000 | $11,403,000 |
| Cash Flow From Continuing Financing Activities | $4,259,000 | $24,500,000 | $35,602,000 | $11,403,000 |
| Net Common Stock Issuance | $7,329,000 | $28,591,000 | $35,602,000 | $8,861,000 |
| Common Stock Issuance | $7,329,000 | $28,591,000 | $35,602,000 | $8,861,000 |
| Net Preferred Stock Issuance | - | - | - | $7,281,000 |
| Preferred Stock Issuance | - | - | - | $7,281,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-6,426,000 | $-4,398,000 | $0 | $-4,739,000 |
| Interest Paid Supplemental Data | $192,000 | $1,177,000 | $1,249,000 | $1,539,000 |
| Income Tax Paid Supplemental Data | $43,000 | $54,000 | $191,000 | $18,000 |
| End Cash Position | $8,150,000 | $30,711,000 | $39,673,000 | $31,598,000 |
| Beginning Cash Position | $30,711,000 | $39,673,000 | $31,598,000 | $51,829,000 |
| Changes In Cash | $-22,561,000 | $-8,962,000 | $8,075,000 | $-20,231,000 |
| Proceeds From Stock Option Exercised | $3,356,000 | $307,000 | $0 | $7,281,000 |
| Net Issuance Payments Of Debt | $-6,426,000 | $-4,398,000 | $0 | $-4,739,000 |
| Net Long Term Debt Issuance | $-6,426,000 | $-4,398,000 | $0 | $-4,739,000 |
| Long Term Debt Payments | $-6,426,000 | $-4,398,000 | $0 | $-4,739,000 |
| Net PPE Purchase And Sale | $0 | $-435,000 | $-170,000 | $-562,000 |
| Purchase Of PPE | $0 | $-435,000 | $-170,000 | $-562,000 |
| Change In Working Capital | $-5,130,000 | $1,613,000 | $-2,677,000 | $868,000 |
| Change In Other Current Liabilities | $-870,000 | $-1,101,000 | $-1,631,000 | $-1,501,000 |
| Change In Payables And Accrued Expense | $-4,875,000 | $2,824,000 | $-1,239,000 | $1,454,000 |
| Change In Accrued Expense | $-3,463,000 | $1,219,000 | $-976,000 | $1,453,000 |
| Change In Interest Payable | $-59,000 | $-54,000 | $16,000 | $-256,000 |
| Change In Payable | $-1,412,000 | $1,605,000 | $-263,000 | $1,000 |
| Change In Account Payable | $-1,412,000 | $1,605,000 | $-263,000 | $1,000 |
| Change In Prepaid Assets | $615,000 | $-110,000 | $193,000 | $915,000 |
| Other Non Cash Items | $1,188,000 | $1,511,000 | $1,884,000 | $1,570,000 |
| Stock Based Compensation | $3,118,000 | $5,303,000 | $2,546,000 | $1,561,000 |
| Depreciation Amortization Depletion | $266,000 | $389,000 | $381,000 | $638,000 |
| Depreciation And Amortization | $266,000 | $389,000 | $381,000 | $638,000 |
| Depreciation | $266,000 | $389,000 | $381,000 | $638,000 |
| Net Income From Continuing Operations | $-26,262,000 | $-41,843,000 | $-29,491,000 | $-35,709,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
Fetched: 2026-10-18